ATHX
$1.39
Athersys
$.04
2.96%
ATHX
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.07)
Revenue:  N/A
Wednesday
Feb 5
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, November 06, 2019

What do you expect when ATHX reports earnings?
Beat
Meet
Miss

Where is ATHX's stock price going from here?
Up
Flat
Down
Stock chart of ATHX
Analysts
Summary of analysts' recommendations for ATHX
Score
Grade
Pivots
Resistance
$1.49
$1.44
$1.42

$1.37

Support
$1.35
$1.30
$1.28
Tweet
Growth
Description
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsCelgeneInterCeptJohnson & JohnsonMylanZoetisEndo International plcUltragenyx Pharmaceutical